

SIMRIS GROUP

YEAR-END REPORT

JANUARY–DECEMBER 2025

QUARTER 4, JULY – DECEMBER 2025

- Net revenue decreased by 71% to SEK 285k (971k).
- EBITDA declined by 63% to SEK -5 196k (-3 180k).
- EBIT/Operating result improved by 9% to SEK -8 429 (-9 241k).

YEAR-END PERIOD, JANUARY – DECEMBER 2025

- Net revenue decreased by 44% to SEK 1 615k (2 890k).
- EBITDA improved by 12% to SEK -15 539k (-17 593k).
- EBIT/Operating result improved by 15% to SEK -29 562k (-34 714k).

KEY EVENTS DURING THE QUARTER

- Simris Biologics GmbH announced important progress in its ongoing preclinical study with Nuvisan, a leading European contract research and development organization.
- Simris Group announces leadership transition - Daniel Kubitzka appointed interim CEO.
- Simris Group has entered into a bridge loan agreement with Osiris International Trustees Limited as Trustee of Mountain High Trust. The Bridge Loan amounts to a total of EUR 200,000 and the monthly interest rate is 1,0 percent.
- The Board resolved on a directed issue of 330 000 000 units (1 share + 2 warrants series 2025/2027) at SEK 0.05 per unit, raising approx. EUR 1.5 million before costs, corresponding to 330,000,000 new B shares and 660,000,000 warrants (each warrant exercisable at SEK 0.05 until 31 December 2027).
- Conversion of convertible bonds following the directed unit issue qualifying as a financing event, holders of convertibles totaling SEK 7.6 million requested conversion at SEK 0,035 per share (70% of the unit issue price), resulting in the issuance of 216 960 000 new class B shares.

KEY EVENTS AFTER THE END OF THE QUARTER

- Simris Group enters into Memorandum of Understanding regarding divestment of assets in Hammenhög.
- Extraordinary General Meeting 19 January 2026 resolved to elect Julian Read as new board member, adopt new articles of association with increased share capital limits and share limits, and approve (i) a directed issue of units to investors at SEK 0.05 per unit, each unit consisting of one share and two warrant, corresponding to 140 905 267 units (ii) a directed issue of class B shares to management at SEK 0.05 per share, corresponding to 36 783 108 number shares.

THE PERIOD IN BRIEF - GROUP

SEK thousands	Oct-Dec 2025	Oct-Dec 2024	Δ	Full year 2025	Full year 2024	Δ
Net revenue	285	971	-71%	1 615	2 890	-44%
EBITDA	-5 196	-3 180	-63%	-15 539	-17 593	12%
EBIT / Operating result	-8 429	-9 241	9%	-29 562	-34 714	15%
Result before tax	-7 945	-10 673	26%	-30 003	-38 178	21%
Cash flow from operating activities	-4 319	-1 568	175%	-16 045	-18 016	11%
Cash at the end of the period	1 465	1 946	-25%	1 465	1 946	-25%

CEO UPDATE

Our vision is to build the leading antibody-drug conjugate (ADC) payload company in the industry — pioneering a new generation of payloads that deliver a breakthrough in safety.

On the back of the successful proof-of-concept trials mentioned in the previous report, we initiated the first step of another in-vivo study programme in December. In January, our partner Nuvisan reported challenges in the stability of the ADC constructed for the study, and as such the results were inconclusive. Based upon this experience, we have activated a plan to produce new ADCs using different bioconjugation strategies and several structural variants of Microcystin payloads, with the goal to identify the optimal Pre-Clinical Candidate (PCC) to take into Investigational New Drug (IND) enabling studies.



Also in December, Simris completed a funding round that included the conversion of a large portion of the Company's debt as part of our ongoing efforts to strengthen and stabilise the Company's financial position. This included restructuring outstanding loans, converting debt into equity and completing targeted capital injections. While these measures have been dilutive, they have significantly reduced our debt burden and strengthened our equity base. Importantly, the transactions also brought in new cash to the Company, improving short-term liquidity and giving us the financial runway required to continue operations.

I am extremely happy that we were able to bring Julian Read back into the business as board member. His strategic thinking, knowledge of the industry, experience in transformation and investor relations are a significant boost for Simris and I am delighted to have him back on board.

Finally, we announced a memorandum of understanding with the French company Immunrise, who are currently concluding legal, technical and operational due diligence for the acquisition of Simris' assets in Hammenhög, Sweden. We are optimistic that that the Company will close this deal, thereby completing Simris' transformation from a food supplement to a biotech company.

The market for ADC's continues to grow rapidly and driven by:

- The expansion for outpatient ADC administration.
- A rapidly expanding >65-year-old demographic and associated increase in tumour diseases.
- The approval of new ADCs for expanded indications.

ADC revenues were \$13bn in 2024 an increase of 25% on the previous year and are forecast to continue growing at a CAGR of 10%* into the 2030's. In addition to the three points above, further growth of the ADC market will be stimulated by:

- Accelerated R&D funding and clinical trial initiations.
- Growing pharma investments (M&A and license deals).
- An increasing demand for effective, low-toxicity drugs.
- Novel payload classes, including a growing diversification into other biological inhibitors, contributing to a broader pool of payloads that can be also used in combination to overcome drug resistance.

Despite the optimism, there are some areas that can hold back growth, namely:

- Production-related payload supply constraints (mainly auristatin/PBD) creating a bottleneck in ADC production.
- High manufacturing complexity and associated safety measures.

Simris' unique platform is a game changer for the industry as it is ideal for overcoming these constraints. Our technology platform enables us to develop effective payloads of both high and low-toxicity tailored for the specific cancer type whilst also improving safety of the payload by avoiding its ability to enter healthy cells. Furthermore, the production of cyanotoxins in cyanobacteria is both immensely scalable and cost effective.

The value of cyanobacterial toxins is already evident. Six of the fourteen FDA-approved and commercially available ADC's, accounting for 40% of the estimated \$13bn sales revenue in 2025, are based upon a cyanotoxin (MMAE & MMAF).

Simris can offer multiple new classes of conjugation-ready cyanotoxins, and other cyclic peptides. All of these can be further optimised for both efficacy and safety via structural modifications covered by Simris IP.

I am so impressed and grateful for the energy and passion that the team is applying their work. They believe strongly in the purpose of their work and the potential of our science.

Finally, I wish to thank all of our shareholders for their continued belief and support in what we are working to achieve. Together we can cure more people of cancers and help them to stay healthy.

*Simris estimates based upon the forecasts of twelve different ADC market intelligence reports.

Daniel Kubitza

Interim CEO Simris Group

The Simris logo is written in a stylized, cursive, teal-colored font.

OVERVIEW

NET REVENUE AND PROFIT

The sales for the quarter decreased by 71% and amounted to SEK 285k (971k) and the sales for the year-end period decreased by 44% and amounted to SEK 1 615k (2 890k).

The EBITDA result for the quarter declined by 63% to SEK -5 196k (-3 180k) and the EBITDA result for the year-end period improved by 12% to SEK -15 539 (-17 593k). The EBIT/ Operating result for the quarter improved by 9% to SEK -8 429k (-9 241k) and the EBIT/ Operating result for the year-end period improved by 15% to SEK -29 562k (-34 714k).

The financial net for the quarter amounted to SEK 484k (-1 432k) and for the year-end period SEK -441k (-3 464k).

The total inventory value amounted to SEK 1077k (509k) at the end of the interim period. All inventory accounted for at the end of the interim period is related to Simris Biologics.

FIXED ASSETS

The total book value of the Group's fixed assets amounted to SEK 131 908k (154 003k) at the end of the year. Intangible Assets at the end of the year were SEK 120 553k (138 974k). Tangible Assets at the end of the year were SEK 11 355k (15 029k).

The depreciation of fixed assets was made according to relevant accounting standards with SEK 3 233k (6 061k) during the quarter. Fixed assets are depreciated over 5–10 years for most fixtures and fittings, and over the remaining lifetime for patents (15 years for the patents and technology gained through the Cyano Biotech acquisition, now renamed to Simris Biologics), and up to 50 years for the buildings.

LIQUIDITY AND FINANCING

Cash flow from operating activities declined by 175 percent to SEK -4 319k (-1 568k) during the quarter and cash flow from operating activities improved by 11 percent to SEK -16 045k (-18 016k) during the year-end period. Cash flow amounted to SEK -2 333k (-24k) for the quarter and cash flow amounted to SEK -481k (-3 719k) for the year-end period. At the end of the period, cash and cash equivalents amounted to SEK 1 465k (1 946k). The total liabilities at the end of the period amounted to SEK 148 851k (151 416k).

The deferred tax liability at the end of the quarter amounting to SEK 36 170k (41 816k) is not a payable debt as it is related to the purchase price allocation of Simris Biologics.

It is important to note that €8m of the long-term debt on the balance sheet is associated with the acquisition of Cyano Biotech (now Simris Biologics). This is the maximum earn-out remaining to be paid for the acquisition of the ADC platform. For this to become payable, Simris Biologics would have to first earn sales revenue of at least €80m from the ADC platform over the next 15 years. This revenue would be expected to be at a very high profit margin. Importantly, Simris Group has executed a back-to-back agreement with Simris Biologics whereby Simris Biologics will recompense Simris Group for the amount of this future earn-out payment.

On December 23, 2024, Simris Group AB (publ) entered into convertible loan agreements totaling €600k with an option for the lender to increase by €900k, and additional convertible loans of €140k to management which were approved by the extraordinary general meeting on January 20, 2025. The lenders shall be able to convert all outstanding loans and accrued interest to B-shares at a subscription price of SEK 0.05 per B-share. Maturity date for the loans is extended to March 31, 2026. At the annual general meeting held on May 28, 2025, Simris Group AB (publ) resolved to extend the maturity date for the loans from board and management. After August 1, 2025 Interest will be charged at 0% per month. Following the resolutions at the extraordinary general meeting held on 19 January 2026, the outstanding loans were set off through a directed issue of 140 905 267 units (each unit consisting of one (1) class B share and two

(2) warrants), corresponding to 140 905 267 new class B shares and 281 810 534 warrants. The share capital increased by SEK 1 409 052,67 as a result of the issuance of the class B shares (and may increase by an additional SEK 2 818 105,34 upon full exercise of the warrants).

The Brand Laboratories FZ (TBL) had previously provided the business with a loan facility of €778k. The facility maturity date is 1 January 2027, and interest was charged at 1.0% per month until 31 July 2025. The total loan including accumulated interest is per 31 July 2025 €856k. After August 1, 2025 Interest will be charged at 0% per month.

On 15 April 2025, Simris Group entered into a bridge loan agreement with Osiris International Trustees Limited, as Trustee of Mountain High Trust, for a loan facility of up to EUR 450 000. After the issue of convertible debentures at the end of July 2025 it's agreed that the bridge loan agreement was terminated.

On 27 July 2025, the Board of Directors of Simris Group AB (publ) resolved to carry out a directed issue of convertible debentures amounting to a nominal maximum of EUR 678,000. The issue was directed to a group of strategic investors, including Praesidio Wealth Solutions Fund SPC Ltd, Osiris International Trustees Limited (as trustee of the Mountain High Trust), Russel Ziman, and Glen Phillip Heneck. The convertibles are interest-free, mature on 31 March 2026, and may be converted into B shares during March 2026. The conversion price will be the lower of SEK 0.125 or 70% of the subscription price in a future capital raise of at least SEK 10 million. A setup fee of 5% (EUR 33,700) is payable 30 days after registration. If fully converted at SEK 0.125 per share, the convertibles would result in a dilution of approximately 8.9%, increasing the share capital by SEK 607,488 through the issuance of 60,748,800 new shares. Following the directed unit issue announced on 16 December 2025, which constituted a qualified financing event under the terms of the convertibles, the holders exercised their right to premature conversion. The convertibles, amounting to SEK 7 593 600, were converted at SEK 0,035 per share (corresponding to 70% of the subscription price in the directed issue), resulting in the issuance of 216 960 000 new class B shares and an increase in share capital of SEK 2 169 600.

On 3 December 2025, Simris Group entered into a bridge loan agreement with Osiris International Trustees Limited, as Trustee of Mountain High Trust, for a loan facility of EUR 200 000. The loan will be offset in January in the Capital Raise below.

On 16 December 2025, the Board of Directors, by virtue of the authorization granted by the annual general meeting held on 28 May 2025, resolved on a directed issue of 330 000 000 units, each unit consisting of one (1) class B share and two (2) warrants of series 2025/2027, at a subscription price of SEK 0.05 per unit. The warrants were issued free of charge. Through the issue, the Company received proceeds of approximately EUR 1,5 million before transaction costs. The issue resulted in the issuance of 330 000 000 new class B shares, increasing the share capital by SEK 3 300 000, from SEK 6 251 448,98 to SEK 9 551 448,98. Each warrant entitles the holder to subscribe for one (1) new class B share at SEK 0.05 during the period up to and including 31 December 2027. Upon full exercise of all warrants, an additional 660,000,000 class B shares may be issued, corresponding to a further increase in share capital of SEK 6,600,000. The transaction was subscribed to in December 2025 and January 2026. Per 31 December 2025 the subscription in the transaction where EUR 1 225k which was accounted as equity and receivable over the year-end. The transaction is fully subscribed and paid for and registered in January 2026.

The Board of Directors wishes to inform stakeholders that the company's current cash reserves may not be sufficient to cover ongoing operations through the end of the calendar year. We recognize the gravity of this situation and are actively working on multiple fronts to secure the necessary funding to support the company's ongoing operations and future growth. Efforts are underway and the board explores various financing options, including debt refinancing, potential loans, new investment opportunities, and strategic partnerships. The Board remains committed to ensuring the long-term stability and success of the company and will continue to update stakeholders as progress is made.

EQUITY

The Group's equity amounted to SEK -470k (5 641k) at the end of the quarter. The solidity was -0,3 percent, compared with 3.6 percent on December 31, 2024.

The total number of shares amounted to 842 104 898 B and the share capital amounted to SEK 8 421 048,98. Each share has a quota value amounting to 0.01 SEK.

OPTION PROGRAM

At the end of the period, Simris Group had no outstanding Option program.

After the year-end Simris Group issued two option programs to capital raise of units.

Series 2025/2027 consists of 660 000 000 options and was issued to the investors in January 2026. The options have a term of three years, and each option gives the right to subscription of one B shares at a subscription price of SEK 0,05 per share until end of 2027. Utilization of outstanding options corresponds to a dilution of the share capital by 48,90 percent.

Series 2026/2027 consists of 281 810 534 options and was issued to the investors in January 2026. The options have a term of three years, and each option gives the right to subscription of one B shares at a subscription price of SEK 0,05 per share until end of 2027. Utilization of outstanding options corresponds to a dilution of the share capital by 20,89 percent.

STAFF AND ORGANIZATION

The average number of full-time equivalents (FTEs) employed during the quarter amounted to 5 (5) and the average number of full-time equivalents (FTEs) employed during the year-end period amounted to 6 (7). At the end of the quarter, the Group had 5 FTEs excluding the CEO and the CFO that are contracted as consultants.

PARENT COMPANY

Simis Group AB is the parent company. Net revenue for the Parent Company during the quarter amounted to SEK 0k (5k) and amounted to SEK 0k (159k) for the year-end period. EBIT/ Operating result amounted to SEK -3 790k (-4 893k) for the quarter and amounted to SEK -11 739 (-16 756k) for the year-end period. Result before tax amounted to SEK -6 466k (-6 061k) for the quarter and amounted to SEK -15 297k (-19 852k) for the year-end period. During the quarter, shares in subsidiary Simris Biologics were written down by SEK 2 690 888,00.

TRANSACTIONS WITH RELATED PARTIES

At the extraordinary general meeting held on January 20, 2025, Simris Group AB (publ) resolved to enter into loan agreements totaling EUR 140 000 with related parties, including Frank Puccio (EUR 50 000), Royce CoLabs AB, a company controlled by Jonathan Royce (EUR 10 000), Magnus Högström (EUR 30 000), Arminnovate Ltd, a company controlled by Dr Alexis Roberts-McIntosh (EUR 20 000), and Christoffer Tell AB, a company controlled by Christoffer Tell (EUR 30 000). Due to conflicts of interest among board members, the agreements were submitted to the general meeting for approval in accordance with the Swedish Companies Act. The loans carry an interest rate of 1.0 percent per month and mature on December 31, 2025. The lenders have the right to convert the outstanding loan amounts, including accrued interest, into B-shares at a subscription price of SEK 0.05 per share, subject to adjustment in the event of a future capital raise. At the annual general meeting held on May 28, 2025, Simris Group AB (publ) resolved to extend the maturity date to March 31, 2026. From 1 August 2025 the interest rate of the loan is 0.0 percent per month. At the extraordinary general meeting held on 19 January 2026, it was resolved that the outstanding loan amounts be set off against newly issued class B shares at a subscription price of SEK 0,05 per share, Frank Puccio 11 654 346 shares, Royce CoLabs AB 2 330 123 shares, Magnus Högström 7 006 032 shares and Christoffer Tell AB 6 992 607 shares.

In addition to normal Board work during the quarter, Board Directors performed consulting services for the company, of which Magnus Högström SEK 28k and Jonathan Royce SEK 29k.

ACCOUNTING PRINCIPLES

Simris Group prepares its accounts in accordance with the Annual Accounts Act and the Accounting Boards general advice 2012:1(K3). Information on accounting principles in general is provided in the Annual Report for 2024.

AUDIT

This report has not been reviewed by Simris Group's auditor.

RISKS AND UNCERTAINTIES

Simris Group's operations, financial position and earnings can be affected by a number of risks and uncertainties. These are described in Simris Group's Annual Report for 2024, at www.simrisgroup.com.

Simris Group is in the start-up phase and still lacks sufficient earnings to cover the costs of the business through sales revenue. Simris Group is reliant upon planned additional external funding to be able to continue its operations, repay loans, and implement growth plans. Whilst the Board is confident that the business is in its strongest position ever, and that it will be able to raise the funds required for future investment and growth, there is always a risk that capital markets change and that new capital cannot be accessed when needed, or that new capital cannot be obtained on satisfactory terms, or that the procured capital is insufficient to finance the planned operations in accordance forecasts and objectives.

28 February 2026

The Board of Directors and the CEO confirm that this report provides a fair overview of the Group's operations, position and results.

Daniel Kubitza
Interim CEO

Jonathan Royce
Chairman

Magnus Högström
Board Director

Frank Puccio
Board Director

Richard Todd
Board Director

Hadrien Forterre
Board Director

Julian Read
Board Director



INCOME STATEMENT - CONSOLIDATED GROUP

SEK thousands	Oct-Dec 2025	Oct-Dec 2024	Full year 2025	Full year 2024
Net revenue	285	971	1 615	2 890
Change of finished goods and work in progress	610	-202	610	-404
Other operating income	264	137	1 780	263
Raw materials and consumables	-167	-196	-460	-1 269
Other external expenses	-4 629	-2 614	-13 259	-11 639
Personnel expenses	-1 559	-1 276	-5 825	-7 434
Depreciation and amortization	-3 233	-6 061	-14 023	-17 121
Operating result / EBIT	-8 429	-9 241	-29 562	-34 714
Financial net	484	-1 432	-441	-3 464
Result before tax	-7 945	-10 673	-30 003	-38 178
Tax	721	1 031	3 192	3 573
Result for the period	-7 224	-9 642	-26 811	-34 605
(Attributable to the parent company's shareholders)	-7 224	-9 642	-26 811	-34 605

BALANCE SHEET - CONSOLIDATED GROUP

SEK thousands	31 Dec 2025	31 Dec 2024
Assets		
Fixed Assets		
Intangible assets	120 553	138 974
Tangible assets	11 355	15 029
Total Fixed Assets	131 908	154 003
Current Assets		
Inventory	1 077	509
Other receivables	13 931	599
Cash and bank balances	1 465	1 946
Total Current Assets	16 473	3 054
Total Assets	148 381	157 057
Equity and Liabilities		
Equity	-470	5 641
Provisions		
Deferred tax	36 170	41 816
Liabilities		
Long-term Liabilities	87 680	93 631
Short-term Liabilities	25 001	15 969
Total Liabilities	148 851	151 416
Total Equity and Liabilities	148 381	157 057

CASH FLOW ANALYSIS - CONSOLIDATED GROUP

SEK thousands	Oct-Dec 2025	Oct-Dec 2024	Full year 2025	Full year 2024
Cash flow from operating activities before changes in working capital	-4 623	-5 105	-15 933	-22 088
Cash flow from working capital	304	3 537	-112	4 072
Cash flow from operating activities	-4 319	-1 568	-16 045	-18 016
Cash flow from investing activities	-224	-613	-224	-613
Cash flow from financing activities	2 210	2 157	15 788	14 910
Cash flow for the period	-2 333	-24	-481	-3 719
Cash and cash equivalents opening balance	3 798	1 970	1 946	5 665
Cash and cash equivalents closing balance	1 465	1 946	1 465	1 946

CHANGES IN EQUITY - CONSOLIDATED GROUP

SEK thousands	Oct-Dec 2025	Oct-Dec 2024	Full year 2025	Full year 2024
Opening balance	-14 259	941	5 641	25 614
Issue	21 069	13 854	21 069	13 854
Issue costs	0	0	0	0
Translation differences	-56	488	-369	778
Result for the period	-7 224	-9 642	-26 811	-34 605
Closing balance	-470	5 641	-470	5 641

KEY FIGURES - CONSOLIDATED GROUP

	Oct-Dec 2025	Oct-Dec 2024	Full year 2025	Full year 2024
Net revenue (kSEK)	285	971	1 615	2 890
EBIT (kSEK)	-8 429	-9 241	-29 562	-34 714
Cash at the end of the period (kSEK)	1 465	1 946	1 465	1 946
Equity (kSEK)	-470	5 641	-470	5 641
Earnings per share (SEK)	neg.	neg.	neg.	neg.
Earnings per share after full dilution (SEK)	neg.	neg.	neg.	neg.
Equity per share (SEK)	-0,001	0,02	-0,001	0,02
Equity per share after full dilution(SEK)	-0,001	0,02	-0,001	0,02
Number of shares, average	629 861 420	348 070 570	574 194 370	348 070 570
Number of shares, end of period	842 104 898	348 070 570	842 104 898	348 070 570
Number of shares after full dilution*	842 104 898	348 070 570	842 104 898	348 070 570
Solidity (%)	-0,3	3,6	-0,3	3,6
Balance sheet total (kSEK)	148 381	157 057	148 381	157 057
Cash liquidity (%)	62	16	62	16
Average number of employees	5	5	6	7

*Simris Group has no outstanding warrant program.

INCOME STATEMENT - PARENT COMPANY

SEK thousands	Oct-Dec 2025	Oct-Dec 2024	Full year 2025	Full year 2024
Net revenue	0	5	0	159
Change of finished goods and work in progress	0	0	0	-202
Other operating income	0	129	28	255
Raw materials and consumables	0	0	0	-249
Other external expenses	-2 898	-1 915	-8 285	-8 772
Personnel expenses	-145	-165	-496	-2 761
Depreciation and amortization	-747	-2 947	-2 986	-5 186
Operating result / EBIT	-3 790	-4 893	-11 739	-16 756
Financial net	-2 676	-1 168	-3 558	-3 096
Result before tax	-6 466	-6 061	-15 297	-19 852
Tax	0	124	0	114
Result for the period	-6 466	-5 937	-15 297	-19 738

BALANCE SHEET - PARENT COMPANY

SEK thousands	31 Dec 2025	31 Dec 2024
Assets		
Fixed Assets		
Tangible assets	9 962	12 947
Financial assets	130 795	132 478
Total Fixed Assets	140 757	145 425
Current Assets		
Inventory	0	0
Other receivables	13 528	433
Cash and bank balances	1 097	909
Total Current Assets	14 625	1 342
Total Assets	155 382	146 767
Equity and Liabilities		
Equity	43 972	38 201
Provisions		
Deferred tax	0	0
Liabilities		
Long-term Liabilities	87 680	93 631
Short-term Liabilities	23 730	14 935
Total Liabilities	111 410	108 566
Total Equity and Liabilities	155 382	146 767

ABOUT SIMRIS GROUP

Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics. Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

FINANCIAL CALENDAR:

Annual Report 2025	15 April 2026
Interim Report Q1, 2026	13 May 2026
Annual General Meeting	27 May 2026
Interim Report Q2, 2026	12 August 2026
Interim Report Q3, 2026	11 November 2026
Year-end Report 2026	24 February 2027

Certified Adviser

Amudova AB is the Company's Certified Adviser on Nasdaq First North and can be reached at info@amudova.se or +46 (0) 8-546 017 58.

FOR MORE INFORMATION:

Daniel Kubitza, interim CEO
 Phone: +33 6 71 04 21 52
 Email: IR@simris.com

KEY FIGURE DEFINITIONS

Balance sheet total - The sum of all assets in the balance sheet or sum of all liabilities and equity.

Equity per share - Adjusted equity (equity and untaxed reserves less deferred tax) divided by the number of shares at the end of the period.

Equity per share after full dilution - Adjusted equity (equity and untaxed reserves less deferred tax) divided by the number shares at the end of the period taking into account after conversion and adjusted for effect of share-based payments.

Cash liquidity - Current assets excluding inventories and work in progress as a percentage of current liabilities

Net revenue - Operating main income, invoiced costs, side income and income corrections.

Earnings per share - Earnings for the period divided by the number of shares after the end of the period.

Earnings per share after full dilution - Earnings for the period divided by number shares after the end of the period, taking into account after conversion and adjusted for effect of share-based payments.

EBIT/ Operating result - Result before financial expenses and tax.

Solidity - Adjusted equity at the end of the period as a percentage of total asset.

This information is information that Simris Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on 28 February 2026.

